Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.
OBJECTIVE
The aim of this retrospective study was to determine whether glucose metabolism assessed by using Fluorine-18 (F-18) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) provides prognostic information independent of established prognostic factors in patients with Ewing sarcoma.


METHODS
We retrospectively reviewed the medical records of 34 patients (men, 19; women, 15; mean age, 14.5 ± 9.7 years) with pathologically proven Ewing sarcoma. They had undergone F-18 FDG PET/CT as part of a pretreatment workup between September 2006 and April 2012. In this analysis, patients were classified by age, sex, initial location, size, and maximum standardized uptake value (SUVmax). The relationship between FDG uptake and survival was analyzed using the Kaplan-Meier method with the log-rank test and Cox's proportional hazards regression model.


RESULTS
The median survival time for all 34 subjects was 999 days and the median SUV by using PET/CT was 5.8 (range, 2-18.1). Patients with a SUVmax ≤ 5.8 survived significantly longer than those with a SUVmax > 5.8 (median survival time, 1265 vs. 656 days; p = 0.002). Survival was also found to be significantly related to age (p = 0.024), size (p = 0.03), and initial tumor location (p = 0.036). Multivariate analysis revealed that a higher SUVmax (p = 0.003; confidence interval [CI], 3.63-508.26; hazard ratio [HR], 42.98), older age (p = 0.023; CI, 1.34-54.80; HR, 8.59), and higher stage (p = 0.03; CI, 1.21-43.95; HR, 7.3) were associated with worse overall survival.


CONCLUSIONS
SUVmax measured by pretreatment F-18-FDG PET/CT can predict overall survival in patients with Ewing sarcoma.
Department of Nuclear Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Jae Pil
JP
Hwang
Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.|Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Ilhan
I
Lim
Department of Orthopedic Surgery, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Chang-Bae
CB
Kong
Department of Orthopedic Surgery, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Dae Geun
DG
Jeon
Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Byung Hyun
BH
Byun
Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.|Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Byung Il
BI
Kim
Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.|Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Chang Woon
CW
Choi
Department of Nuclear Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.|Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Sang Moo
SM
Lim
D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000401:mortality / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D049268:Positron-Emission Tomography; D016016:Proportional Hazards Models; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012512:Sarcoma, Ewing / Q000401:mortality / Q000473:pathology*; D014057:Tomography, X-Ray Computed / Q000379:methods*; D055815:Young Adult
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D005947:Glucose